Industry
Biotechnology
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:36 pm
Portfolio Pulse from Avi Kapoor
July 23, 2024 | 5:21 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 9:22 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Insights
May 28, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 11:50 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.